|
Ovarian Cancer
 In 2009, an approximate 21,550 women were diagnosed with ovarian cancer and 14,600 women succumbed to this disease
(Source: American Cancer Society). This high mortality rate is in stark contrast with the observation that 90 percent of ovarian cancers can be treated at stage I with the currently existing surgical and chemotherapeutic regimens. With only 25 percent of ovarian cancers detected at this treatable stage, these survival benefits are not being realized presently.
Ovarian cancer with its ‘silent’ symptoms and the lack of effective screening procedures, presents itself at an advanced stage where the long term survival has been reported to be less than 30 percent. The McDevitt Lab-on-a-chip sensor group in collaboration with Dr. Robert Bast Jr. at the UT M. D. Anderson cancer research center are currently working on strategies to utilize the Lab-on-a-chip based sensor for effective screening in ovarian cancer. (Read more about McDevitt research collaborators.)
Accomplishments
- Jokerst, J.V. et al. Bio-nano-chips for high performance multiplexed protein detection: Determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosensors and Bioelectronics 24, 3622-3629 (2009). (Read more or return to Cancer Research Home)
|
